C
Calithera Biosciences Inc
F:2CB
Calithera Biosciences Inc
F:2CB
Price:
3.86
EUR
-2.53%
Market Closed
Market Cap:
€1m
Relative Value
There is not enough data to reliably calculate the relative value of 2CB.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
2CB
Relative Value
Base Case
Not Available
Multiples Across Competitors
2CB Competitors Multiples
Calithera Biosciences Inc Competitors
Calithera Biosciences Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
C
|
Calithera Biosciences Inc
F:2CB
|
1m EUR | 0 | -0.1 | 0.6 | 0.6 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 643 258.8 | -159 901.4 | -194 171.3 | -191 955.6 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
391.4B USD | 6.6 | 166.9 | 16.2 | 23 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
203.4B USD | 5.5 | 26.1 | 15 | 15 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
189.1B USD | 6.4 | 23.1 | 15.7 | 15.7 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
120.9B USD | 10.2 | 32.6 | 24 | 25 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 094 | -534.3 | -581.8 | -566.3 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
82B USD | 5.7 | 18.1 | 15.4 | 17.6 | |
| AU |
|
CSL Ltd
ASX:CSL
|
87.4B AUD | 3.9 | 20.2 | 13.5 | 16.9 | |
| NL |
|
argenx SE
XBRU:ARGX
|
42.2B EUR | 14.1 | 33 | 56.3 | 57.9 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.2 | -61.8 | -66.7 | -60.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
